Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Sign Up to like & getrecommendations! Published in 2019 at "Fertility and sterility"
DOI: 10.1016/j.fertnstert.2019.07.013
Abstract: OBJECTIVE To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid-associated pain. DESIGN Phase 3, multicenter, randomized, double-blind, placebo-controlled study. SETTING Centers. PATIENT(S) Premenopausal Japanese women… read more here.
Keywords: relugolix; treatment; study; oral gonadotropin ... See more keywords
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2020 at "Fertility and sterility"
DOI: 10.1016/j.fertnstert.2020.07.055
Abstract: OBJECTIVE To evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain. DESIGN Phase 2, multicenter, randomized, double-blind, placebo-controlled… read more here.
Keywords: dose response; response manner; relugolix; associated pain ... See more keywords
Relugolix Combination Therapy Improves Hemoglobin Levels in Anemic Women with Uterine Fibroids: Results from the Liberty Phase 3 Program
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Minimally Invasive Gynecology"
DOI: 10.1016/j.jmig.2020.08.315
Abstract: Study Objective To evaluate the effect of Relugolix combination therapy (Rel-CT) on hemoglobin in women with uterine fibroids (UF) and anemia. Design LIBERTY 1 and 2 are phase 3, multinational, randomized, double-blind, placebo-controlled studies. Setting… read more here.
Keywords: relugolix; volume; relugolix combination; uterine fibroids ... See more keywords
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "BMC Women's Health"
DOI: 10.1186/s12905-021-01475-2
Abstract: Background Uterine leiomyomas are the most common neoplasm affecting women and frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone (GnRH) receptor antagonists provide fast symptom relief and show promise as a medical (non-surgical) treatment… read more here.
Keywords: uterine leiomyomas; relugolix; trial; treatment ... See more keywords
An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.874973
Abstract: Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, has been well studied in the treatment of endometriosis symptomatic. It is mainly metabolized by the CYP3A subfamily of P450 enzymes, while minorly metabolized by CYP2C8. Daidzein in… read more here.
Keywords: efficient uplc; day; daidzein; relugolix ... See more keywords